Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Lymphangioma × 90 days × Clear all

Phase

Phase 2 3 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 13 Neoplasm Metastasis 12 Breast Neoplasms 12 Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 7 Recurrence 6 Prostatic Neoplasms 6 Myasthenia Gravis 6 Lung Neoplasms 6 Ovarian Neoplasms 5 Leukemia, Myeloid, Acute 5 Colorectal Neoplasms 5 Rectal Neoplasms 4 Precursor Cell Lymphoblastic Leukemia-Lymphoma 4 Multiple Myeloma 4 Glioblastoma 4 Fallopian Tube Neoplasms 4 Urinary Bladder Neoplasms 3 Pancreatic Neoplasms 3 Oropharyngeal Neoplasms 3 Myelodysplastic Syndromes 3 Mouth Neoplasms 3 Melanoma 3 Lymphoma, Large B-Cell, Diffuse 3 Laryngeal Neoplasms 3 Colonic Neoplasms 3 Carcinoma, Hepatocellular 3 Carcinoma 3 Adenocarcinoma Of Esophagus 3 Uterine Cervical Neoplasms 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05948943 2026-02-13

EPIK-L1

Novartis

Phase 2/3 Recruiting

Lymphangioma, Lymphangioma, Cystic, Lymphatic Abnormalities

Data powered by HemOnc (CC BY 4.0) Colophon ⚡